Singapore markets close in 2 hours 54 minutes

Amyris, Inc. (AMRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7000-0.0500 (-2.86%)
At close: 04:00PM EST
1.6800 -0.02 (-1.18%)
After hours: 07:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.7500
Bid0.0000 x 4000
Ask0.0000 x 1300
Day's range1.6684 - 1.7550
52-week range1.2500 - 5.3100
Avg. volume6,754,088
Market cap617.936M
Beta (5Y monthly)1.04
PE ratio (TTM)N/A
EPS (TTM)-0.3870
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.02
  • Motley Fool

    Why Amyris Stock Was Driven Into the Ground on Wednesday

    Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. After market hours on Tuesday, Amyris divulged its third-quarter results. Alas, the total fell far short of the average analyst estimate of just under $112 million.

  • Zacks

    Amyris, Inc. (AMRS) Reports Q3 Loss, Misses Revenue Estimates

    Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    Why Amyris Stock Tumbled This Week

    Amyris had a good news/bad news Tuesday, with the market deciding that the latter outweighed the former. The good was that three of the specialized biotech company's products will be included in the offerings of Sephora when the big cosmetics retailer launches its U.K. website. While having three out of the undoubtedly many Sephora products on the site isn't considerable and thus won't generate monster sales, being in that selection is indisputably a positive development for Amyris.